TyraTech
<< < > >>
Search:
 
| Full PDF report | Print this page |
Annual Report & Accounts 2014 - Director's Report
slide
<< < > >>
TYRATECH • ANNUAL REPORT 2014 • PAGE 11 Regulatory investigations and litigation may lead to fines or other penalties There is a risk that TyraTech would face regulatory investigation and potentially litigation if there were data errors in the submission documents or if new data came out that impacted the claims or safety profile of the product. DIRECTORS The directors who served during 2014 were as follows: A.J. Reade B.M. Riley J. Hills E. Wintemute B. Jactel BIOGRAPHIES OF THE DIRECTORS FOLLOW: Alan Reade was appointed on 25 May 2007 as a Non-Executive Director. In 2010 he became the Executive Chairman and then, in June 2013, he became the Non-Executive Chairman. He is owner of Global Strategy Expression Limited, a consulting and advisory services business in the life sciences industry. From 2000 until his retirement in 2005, he served as Executive Chairman of Merial Limited, a leading animal health company and joint venture between Merck & Co. Inc. and Sanofi-Aventis. Earlier in his career he was head of global integration at Aventis, where he was in charge of merger integration. Prior to that, he was Chief Executive Officer at Rhone-Poulenc Agro Inc. and member of the Global Executive Committee. He is Chairman of the Nomination Committee and a member of the Audit Committee. Barry Riley (Non-Executive Director) was appointed on 25 May 2007. After qualifying as a Chartered Accountant, he joined the Bowater Organization, where he had responsibility for the finance function at several operations. From there he moved to FMC Corporation, the U.S. conglomerate where he had finance and general management responsibilities for a specialty chemical operation, and also oversaw the head office finance function for all UK operations. He joined Proteus International PLC in 1995 as Finance Director and was closely involved in the merger with Therapeutic Antibodies Inc. in 1999, which became Protherics PLC where he was Finance Director until 2007. He is chairman of the Audit Committee and a member of the Remuneration Committee. James Hills (Non-Executive Director) was appointed on 09 July 2010. Mr. Hills spent the early portion of his career with The Gillette Company and Coca Cola USA where he held senior positions in both sales and brand management. Later, he was a 50% partner and Chief Executive Officer of Weatherly Consumer Products Inc., a company which developed, branded and marketed specialty fertilizers in North America and Europe, under the Jobe's brand name. Following the sale of that business in 1996, he started Gulfstream Home and Garden, a company which marketed lawn and garden insecticides under the Sevin brand name in the U.S. He sold that business in 2005 following nearly ten years of rapid growth. Mr. Hills is chairman of the Remuneration Committee and a member of the Nomination and Audit Committees. Bruno Jactel, D.V.M. was appointed as Chief Executive Officer of TyraTech effective 10 January 2013. Dr. Jactel spent 12 years at Merial Limited, the $2.6 billion revenue generating Animal Health subsidiary of the Sanofi Group, most recently serving as combined Chief Strategy Officer and Chief Marketing Officer. As head of commercial operations in Europe, Dr. Jactel developed successful growth strategies in both OTC and professional channels. Prior to working at Merial, Dr. Jactel was Deputy Minister for Economic and Commercial Affairs at the French Embassy in Washington, D.C. He was also a recent founder and board member of Hypercell Technologies LLC, an early-stage biotech company developing therapeutic solutions to serious infectious animal disease. Dr. Jactel is a Doctor of Veterinary Medicine and has a Masters in Economic Sciences from the Sorbonne University in Paris. He graduated from the École Nationale d'Administration, Paris in 1993. Eric Wintemute was appointed to the Board as a Non-Executive Director on 20 June 2013. Mr. Wintemute was elected to the post of AMVAC's President and American Vanguard Corporation's Chief Executive Officer in mid-1994. Mr. Wintemute had joined AMVAC in January 1994 as Executive Vice President, Chief Operating Officer, and a member of the Board of Directors